Sat Kartar Life Ltd Q4 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/vemi3u02paxsvn10vgk31laf.pdf

Key Takeaways


The Repeat Engine


Cost Structure & Margin Levers

Manprit Singh Chadha: "We consider advertisement as an investment and not as a putting in money and then looking for it."

Operational Resilience & Asset-Light Model


Growth Geography & Channels


Product & Category Expansion

Manprit Singh Chadha: "what began as a simple vision to make high-quality Ayurveda accessible across India has evolved into a data-driven wellness platform that sits at the intersection of tradition, technology, and scale."

Competitive Positioning

Manprit Singh Chadha: "It's not because of my exclusive product; it's because of my exclusive human-to-human language-centric interaction."

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue aspirationReach ₹500 crores top lineThree years
First revenue milestoneTouch ₹250 crores within the three major product segmentsUnspecified (stepping stone to ₹500 crores)
Pin code expansionScale from 11,600 to over 19,000 pin codesNext 12 to 18 months
PAT marginAt least 9% to 10% (FY26 internal benchmark)FY26
EBITDA margin15% to 20%Unspecified
YoY revenue growth40%-50%, with ~7% QoQ cumulative growthOngoing
North brand ambassadorAnnouncement expectedNext 15 days
Spiritual offeringsA few SKUs added, update providedBy next earnings call
Monthly revenue updatesProvide monthly revenue disclosuresStarting now
Export strategyNo exportsAt least next six months; reconsider at end of FY26

Key Metrics

MetricQ4 FY25
Revenue₹48 cr (Q4 FY25), FY25 total ₹162.92 cr, +28% YoY
PAT₹9.82 cr (FY25), +55.63% YoY
PAT margin6% (FY25), targeting 9–10% in FY26
Revenue growth guidance40–50% (FY26), implying ₹230–240 cr
PAT margin guidance9–10% (FY26 internal benchmark)
Advertisement cost40–42% of revenue
Repeat customer ratio25%, up from ~22% earlier
Consumer databaseOver 3 crore consumers
Multilingual customer advisors800-plus
Pin code reachOver 11,600, scaling to 19,000 in 12–18 months
Revenue concentration4 of 16 remedies contribute 80% of revenue
Salary and infrastructure cost26–28% of revenue, capacity supports turnover up to ₹210 cr
Q4 FY25 PAT margin~7% (per an analyst's math)